Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2016, Article ID 8219317, 4 pages
http://dx.doi.org/10.1155/2016/8219317
Case Report

Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?

Department of Rheumatology, Nova Southeastern University/Larkin Hospital, Coral Springs, FL, USA

Received 18 September 2016; Revised 20 November 2016; Accepted 27 November 2016

Academic Editor: Mario Salazar-Paramo

Copyright © 2016 Naveen Raj and Barry Waters. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Activation of the classical pathway complement system has long been implicated in stimulating immune complex mediated tissue destruction in systemic lupus erythematosus (SLE). C3 and C4 complement levels are utilized as part of SLE diagnosis and monitoring criteria. Recently, cell bound complement activation products (CBCAPs) have shown increased sensitivity in diagnosing and monitoring lupus activity, compared to traditional markers. CBCAPs are increasingly utilized in rheumatology practice as additional serological markers in evaluating SLE patients. We report a case of a patient diagnosed with SLE that had chronically low C3 and C4, along with negative CBCAPs. We surmise that the patient has an inherited complement deficiency as the etiology of her SLE and that CBCAPs could be used to predict such deficiency.